ArticleBiotechnology for biofuels and bioproducts2026
Metabolic engineering of Bacillus subtilis for high-yield surfactin production.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The industrial application of surfactin has been constrained by the low production capacity of Bacillus subtilis. This study developed a high-yield, high-tolerance surfactin-producing strain through a multi-level metabolic engineering strategy. First, we constructed an enhanced P43 promoter (P43LN) by extending its upstream region from 260 to 520 bp and pairing it with a cognate 5' UTR, which exhibited more than threefold higher activity than the commonly used core P43 promoter, providing a versatile tool for stable and high-level expression of key genes. Based on this, the native srfA promoter in the oilfield-derived B. subtilis TD7 was replaced with the P43 promoter, yielding the engineered strain TP1. Subsequently, systematic knockout of competing antimicrobial peptide synthesis gene clusters (pps, bac, and pks) increased surfactin titer to 2.78 g/L. Further synergistic enhancement of NADPH regeneration (via zwf overexpression) and cellular tolerance (via efflux pump gene yerP overexpression) resulted in the final strain TS8, which achieved a shake-flask surfactin titer of 3.51 g/L, representing a 102.7% increase in per-OD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.